SIRPant Technology for anti-Cancer Immunity
SIRPant 抗癌免疫技术
基本信息
- 批准号:10900882
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAntibodiesAntigen PresentationAntigensAtlasesBiodistributionBiological AssayBody WeightBreastBusinessesCD47 geneCancer PatientCancer RelapseChronicClinicalClinical TrialsColorectalColorectal CancerColorectal NeoplasmsCytotoxic T-LymphocytesDataDendritic CellsDetectionDevelopmentDevelopment PlansDisease remissionDistalDoseEatingExhibitsFDA approvedFundingGoalsHeadHematologyHumanHuman PathologyITIMImmuneImmune EvasionImmune checkpoint inhibitorImmunityImmunocompetentImmunologic MemoryImmunologic SurveillanceImmunophenotypingImmunotherapeutic agentImmunotherapyIn SituInflammatoryInflammatory ResponseInnate Immune ResponseLegal patentLesionLicensingLigationLiquid substanceLongevityLungMacrophageMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMediatingMinorityModalityModelingMusNeoplasm MetastasisOrganPTPNS1 genePatientsPeripheral Blood Mononuclear CellPhagocytesPhagocytosisPhasePhase I Clinical TrialsProductionProtocols documentationRadiation therapyReagentReceptor SignalingRecurrenceReproducibilityResearchScheduleSkinSmall Business Technology Transfer ResearchSolid NeoplasmT memory cellT-Cell ActivationT-LymphocyteTechnologyTechnology TransferTherapeuticToxic effectToxicologyTranslationsTumor AntigensTumor EscapeTumor ImmunityTumor stageValidationWorkXenograft procedureadaptive immune responseadaptive immunityanti-cancercancer cellcancer immunotherapycancer therapycancer vaccinationcarcinogenesisclinical applicationclinical translationcommercializationcytokine release syndromeempowermentextracellularimmune checkpoint blockadeimmune clearanceimmunogenicin situ vaccinationin vivolymphoid organmalignant breast neoplasmmelanomaneoantigensneoplasm immunotherapypre-clinicalpreclinical efficacypreemptpreventprogramsrelapse preventionresponsetherapeutic developmenttumor
项目摘要
PROJECT SUMMARY
Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpoint
blockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detection
and destruction; however, the result of these endeavors have not been satisfactory given a number of critical
barriers. One of these barriers, and a prominent mechanism by which cancer evades immune surveillance and
elimination, is through the cancer cell expressed CD47 to ligate SIRPα, an ITIMs-containing inhibitory signaling
receptor expressed on macrophages, which serves as a negative regulator that inhibits macrophage
phagocytosis, proinflammatory response and antigen presentation. In our studies, we discovered “Phago-Act”-
a proprietary reagent that downregulates SIRPα expression and empowers SIRPα-deficient macrophages
(SIRPαLow MØs) to be an initiator for triggering potent innate and adaptive anti-cancer immunity. Not only do they
directly phagocytose cancer cells (“liquid”/non-adherent cancer in particular), but SIRPαLow MØs are also capable
of conducting immunogenic antigen presentation to robustly activate tumor-specific cytotoxic T cells (Tc) with
high tumoricidal activities, leading to rapid elimination of late-stage, large-size solid tumors with distal lesions
(mimic metastases). The results of SIRPαLow MØs-initiated responses, which are especially effective in solid
tumors, have been vetted extensively in various pre-clinical solid tumor models including cancers of pancreatic,
colorectal, lung, breasts and skin (melanoma), all of which resist advanced anti-cancer therapies including
immune checkpoint inhibitors and their combinations with RT and other modalities. Moreover, SIRPαLow MØsinduced tumor elimination also leads to long-lasting anti-cancer immunity that prevents recurrence. The goal of
this fast-track STTR is to leverage these important research findings and to accelerate their translation to clinical
implement of scalable SIRPαLow MØ-based immunotherapy – “SIRPant Technology” – to treat a broad spectrum
of cancers and prevent relapse. Our current focus is Solid Tumors. In Phase I, we will extend current studies
and establish reproducible protocols for producing human SIRPαLow MØ from PBMC (Aim I-1). Phase II is to
fund specific IND-enabling CMC refinement (Aim II-1) and toxicology studies (Aim II-2) needed for a Phase I
clinical trial, as well as patient applicable SIRPαLow MØs delivery strategies in combined with RT or/and immune
checkpoint inhibitors (Aim II-3). (These discoveries and therapeutic developments are protected by our filed
patents)
项目摘要
免疫逃避是癌症的标志。各种肿瘤免疫治疗,如免疫检查点
封锁和癌症疫苗,已经开发出克服癌症的能力,以避免免疫检测
然而,这些努力的结果并不令人满意,
隔栏.这些障碍之一,也是癌症逃避免疫监视的一个重要机制,
消除,是通过癌细胞表达的CD 47连接SIRPα,一种含有ITIM的抑制性信号传导
巨噬细胞上表达的受体,其作为抑制巨噬细胞的负调节剂
吞噬作用、促炎反应和抗原呈递。在我们的研究中,我们发现了“Phago-Act”-
一种专有试剂,可下调SIRPα表达并增强SIRPα缺陷巨噬细胞
(SIRPα低MIBs)是引发有效的先天性和适应性抗癌免疫的引发剂。他们不仅
直接吞噬癌细胞(特别是“液体”/非粘附性癌),但SIRPα低水平MIBs也能够
进行免疫原性抗原呈递以稳健地激活肿瘤特异性细胞毒性T细胞(Tc),
高杀肿瘤活性,导致晚期、大尺寸实体瘤和远端病变的快速消除
(模拟转移)。SIRPαLow Mass引发的反应的结果,在固体中特别有效,
肿瘤,已经在各种临床前实体瘤模型中进行了广泛的研究,
结直肠、肺、乳房和皮肤(黑色素瘤),所有这些都抵抗先进的抗癌治疗,包括
免疫检查点抑制剂及其与RT和其他方式的组合。此外,SIRPα低分子量诱导的肿瘤消除还导致防止复发的持久抗癌免疫。的目标
这个快速通道STTR是为了利用这些重要的研究成果,并加速其转化为临床
实施可扩展SIRPα低分子量免疫疗法--“SIRPant技术”--治疗广谱
预防癌症复发。我们目前的重点是实体瘤。在第一阶段,我们将扩大目前的研究,
并建立了从PBMC中制备人SIRPαLow MRNA的可重复性方案(Aim I-1)。第二阶段是
为I期研究所需的特定IND支持CMC改进(目标II-1)和毒理学研究(目标II-2)提供资金
临床试验,以及患者适用的SIRPα低MRNA递送策略与RT或/和免疫
检查点抑制剂(Aim II-3)。(这些发现和治疗进展受我们的保护。
专利)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathanael McCurley其他文献
Nathanael McCurley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nathanael McCurley', 18)}}的其他基金
Strategies for Personalized Gene Repair using I22I Severe Hemophilia-A as a Model
以 I22I 严重甲型血友病为模型的个性化基因修复策略
- 批准号:
8905474 - 财政年份:2015
- 资助金额:
$ 100万 - 项目类别:
相似海外基金
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
8965501 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别:
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
9182818 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别:
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
8854409 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别:
Development ofTherapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells
针对人急性髓性白血病干细胞的治疗性抗体的开发
- 批准号:
G1000729/1 - 财政年份:2010
- 资助金额:
$ 100万 - 项目类别:
Research Grant
The relationship between anti-donor antibodies and acute rejection in lung transplantation
抗供体抗体与肺移植急性排斥反应的关系
- 批准号:
12671311 - 财政年份:2000
- 资助金额:
$ 100万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6347230 - 财政年份:2000
- 资助金额:
$ 100万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6201348 - 财政年份:1999
- 资助金额:
$ 100万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6100126 - 财政年份:1998
- 资助金额:
$ 100万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6235545 - 财政年份:1997
- 资助金额:
$ 100万 - 项目类别:
HUMAN AND MURINE HYBRIDOMA ANTIBODIES IN ACUTE LEUKEMIAS
急性白血病中的人和鼠杂交瘤抗体
- 批准号:
3172843 - 财政年份:1983
- 资助金额:
$ 100万 - 项目类别: